STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2020 – 30.09.2020. The report is available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
“Despite significant challenges for society and businesses caused by the Covid-19 pandemic, the third quarter offered good progress for our business. We have been very busy executing our ambitious STENOCARE 2.0 strategy and look forward to continuing our progress in the final quarter of the year.”
|Total income *)||0||0||93||4,942||16,206|
|Operating profit before depreciation (EBITDA)||-2,492||-3,557||-7,985||-3,846||4,417|
|Net financial items||-134||-675||-1,637||-676||-2,112|
|Result per share (DKK)||-0.19||-0.37||-0.77||-0.40||0.19|
Result per share: The result for the period divided by the average number of shares. Total number of shares as of September 30, 2020, amounted to 11,676,126 (8,942,762). Average number of shares for the third quarter 2020 was 11,676,126 (8,942,762).
Solidity: Equity divided by total capital.
*Total income incl. net sales and other income.
Highlights during the period
- August 2020, STENOCARE announced that the Company’s shares have been included on the BSRM segment of the Börse Berlin under the code number A2N6HF.
- August 2020, STENOCARE published its interim report for the second quarter and first half-year of 2020. The interim report is available on the Company’s website (www.stenocare.com)
- September 2020, the Company announced its expectations on supplying medical cannabis oil products to Swedish patients during 2020, through their Canadian supplier Emerald Health Therapeutics Inc.
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 05, 2020.